Omni Partners US’s Celularity CELU Stock Holding History

Omni Partners US’s Portfolio CELU Stock Details CELU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-20,345	Closed	-$2.07M	–	247
2021 Q2	$2.07M	Buy	+20,345	New	+$2.06M	0.09%	113

Other funds holding CELU

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

LOAMU

Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Omni Partners US's CELU Position: Q3 2021 in Review

Omni Partners US sold out of Celularity (CELU) in Q3 2021, closing a stake of 20,345 shares — an estimated $2.07M sold.

Omni Partners US first reported a position in CELU in Q2 2021 and held it in 1 quarter. The position peaked at $2.07M in Q2 2021. 21 funds tracked by Wall St. Rank hold CELU as of Q3 2021.

Omni Partners US reported no remaining Celularity position as of Q3 2021 after selling out during the quarter.
Omni Partners US sold 20,345 Celularity shares in Q3 2021, an estimated $2.07M.
Omni Partners US first reported a position in Celularity in Q2 2021 and held it in 1 quarter.
Omni Partners US's Celularity position peaked at $2.07M in Q2 2021.
21 funds tracked by Wall St. Rank held Celularity as of Q3 2021.

Based on Omni Partners US's 13F filing for Q3 2021, filed 15 Nov 2021.